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Introduction
Cancer is a collection of diseases whose common feature is
uncontrolled cell proliferation. The phosphorylation of proteins
on serine or threonine residues that immediately precede a pro-
line (pSer/Thr-Pro), so-called Pro-directed phosphorylation, is a
central signaling mechanism controlling normal cell proliferation
and malignant transformation (Blume-Jensen and Hunter,
2001; Lu et al., 2002b). Ser/Thr-Pro motifs are the exclusive
phosphorylation sites for a large number of Pro-directed protein
kinases that play essential roles in signal transduction and cell
cycle progression. Furthermore, many oncogenes and tumor
suppressors themselves are directly regulated by Pro-directed
phosphorylation and/or can trigger signaling pathways involving
Pro-directed phosphorylation.
Significant progress has been made in elucidating the
mechanisms controlling Pro-directed phosphorylation and its
physiological function and pathological importance. However,
little is known about how most Ser/Thr phosphorylation events
regulate protein function, although phosphorylation-induced
conformational changes have been proposed to play a signifi-
cant regulatory role. The recent identification and characteriza-
tion of a peptidyl-prolyl cis/trans isomerase (PPIase), Pin1,
which specifically regulates the conformation of specific Pro-
directed phosphorylation sites in certain proteins, has led to the
discovery of a new postphosphorylation regulatory mechanism
(Lu et al., 1996, 2002b; Ranganathan et al., 1997; Yaffe et al.,
1997). In this mechanism, Pin1 binds to and isomerizes specific
pSer/Thr-Pro motifs and catalytically induces conformational
changes following phosphorylation. Such conformational
changes can have profound effects on the function of many
Pin1 substrates, thereby playing an important role in many cel-
lular events, such as cell cycle progression, transcriptional reg-
ulation, RNA processing, and cell proliferation and
differentiation (Lu et al., 2002b).
Notably, Pin1 is not only overexpressed in a large number of
human cancers, but also is an excellent prognostic marker in
some cancers (Ayala et al., 2003; L. Bao et al., submitted; Ryo
et al., 2001; Wulf et al., 2001). Furthermore, Pin1 overexpres-
sion can function as a critical catalyst that amplifies multiple
oncogenic signaling pathways during oncogenesis (Liou et al.,
2002; Ryo et al., 2001, 2002, 2003; Wulf et al., 2001).
Significantly, inhibition of Pin1 in cancer cells via multiple
approaches triggers apoptosis or suppresses transformed phe-
notype (Lu et al., 1996; Rippmann et al., 2000; Ryo et al., 2002).
In addition, compounds that may selectively inhibit Pin1 are
being identified (Hennig et al., 1998; Uchida et al., 2003).These
results suggest that Pin1-mediated postphosphorylation regula-
tion may provide a unique opportunity for disrupting oncogenic
pathways and represent an appealing target for novel anti-
cancer therapies. The primary focus of this review is to discuss
these promising features of Pin1 as a new molecular target for
cancer diagnostics and therapeutics.
Pro-directed phosphorylation is a central mechanism to
control cell proliferation and transformation
Ser/Thr-Pro motifs are the exclusive phosphorylation sites for
many key protein kinases involved in cell growth control (Lu et
al., 2002b). These include all cyclin-dependent kinases
(CDKs), which control cell cycle transitions, as well as most, if
not all, the mitogen-activated protein kinases (MAPKs), and
glycogen synthase kinase 3β (GSK-3β), which plays key roles
in cell signaling (Figure 1A). Importantly, the ability of these
kinases to phosphorylate the substrates strictly depends on
the presence of a Pro residue that immediately follows Ser/Thr;
its point mutation abolishes phosphorylation and typically dis-
rupts phosphorylation signaling, indicating an essential role of
the Pro residues. Pro residues have the unique property of
existing in two completely distinct isomers, cis and trans, in
folded proteins and therefore can provide a potential backbone
switch in the polypeptide chain that is controlled by cis/trans
isomerization around the peptidyl-prolyl bond (Figure 1A)
(Hunter, 1998; Lu et al., 2002b).
This intrinsically rather slow conversion can be catalyzed by
cis/trans peptidyl-prolyl isomerases (PPIases), which play an
important role in protein folding or refolding (Hunter, 1998).
Cyclophilins and FK506 binding proteins (FKBPs) are two well-
characterized families of PPIases, because they act as cellular
receptors for clinically important immunosuppressive drugs.
However, the PPIase activity of these proteins is neither respon-
sible for the drug action in the immune system nor essential for
cell survival in yeast (Hunter, 1998). Therefore, evidence for the
biological importance of PPIase activity in these proteins has
been elusive. Notably, Pro-directed phosphorylation further
restrains the already slow spontaneous isomerization of pep-
tidyl-prolyl bonds (Lu et al., 2002b;Yaffe et al., 1997). Moreover,
Pro-directed phosphorylation renders the peptide bond resis-
tant to the catalytic action of cyclophilins and FK506 binding
proteins (FKBPs) (Hunter, 1998; Lu et al., 2002b; Yaffe et al.,
1997). Therefore, there is a need for a different enzyme to iso-
merize the Pro-directed phosphorylated peptide bonds.
Pin1 catalyzes conformational changes in certain key Pro-
directed phosphorylation sites and functions as a pivotal
catalyst for oncogenesis
To date, Pin1 is the only enzyme known to specifically isomerize
pSer/Thr-Pro bonds (Figure 1A) (Ranganathan et al., 1997;
Yaffe et al., 1997). Pin1 is highly conserved and its budding
yeast homolog Ess1 is the only known essential gene out of
total 13 known PPIase genes present in the yeast genome (Lu
et al., 1996). The striking substrate specificity of Pin1 toward
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certain pSer/Thr-Pro bonds results from its unique two-domain
structure consisting of an N-terminal WW domain and a C-ter-
minal PPIase domain that form a double-check mechanism
(Ranganathan et al., 1997;Yaffe et al., 1997; Zhou et al., 2000).
The WW domain of Pin1 binds only to specific pSer/Thr-Pro-
motifs, which are often critical regulatory phosphorylation sites
in Pin1 substrates (Lu et al., 1999a, 1999b, 2002b; Ryo et al.,
2001; Shen et al., 1998; Wulf et al., 2001; Zhou et al., 2000).
This WW domain binding targets the Pin1 catalytic domain
close to its substrates, where the PPIase domain isomerizes
specific pSer/Thr-Pro motifs and catalytically induces confor-
mational changes (Lu et al., 1999b; Zhou et al., 2000). The
residues in the Pin1 catalytic site that are responsible for the
phosphorylation specificity are a pair of highly conserved Arg
residues that are not found in other known PPIases
(Ranganathan et al., 1997;Yaffe et al., 1997).
Although protein kinases and phosphatases are trans spe-
cific (Weiwad et al., 2000; Zhou et al., 2000), both cis and trans
pSer/Thr-Pro bonds are likely present in folded phosphopro-
teins. Out of about 105 Ser/Thr-Pro bonds in sequence databas-
es, only ?1% Ser/Thr-Pro bonds can be found in the protein
structure database, and the propensity of cis Ser/Thr-Pro bonds
is in the range of 10%–25%. Since phosphorylation on Ser/Thr-
Pro motifs in peptides does not greatly affect the final equilibri-
um ratio of cis and trans prolyl bonds, the probability of
pSer/Thr-Pro bonds in the cis conformation is estimated to be
10%–20% (Zhou et al., 2000). Given that phosphorylation does
drastically reduce the isomerization rate of the pSer/Thr-Pro
bonds, Pin1 would be needed to accelerate either the trans to
cis or the cis to trans isomerization, depending on specific tar-
get sites, and induce conformational changes in proteins to reg-
ulate their function (Figure 1A). Indeed, Pin1 has been shown to
regulate the catalytic activity, phosphorylation status, protein-
protein interactions, subcellular location, and/or protein stability
of its substrates. These substrates include many essential cell
cycle regulators, oncogenes, and tumor suppressor proteins
known to play important roles in cancer (Figures 1A and 1B)
(Liou et al., 2002; Lu et al., 1999b; Ryo et al., 2001; Shen et al.,
1998; Wulf et al., 2001; Zhou et al., 2000). Thus, Pin1-induced
conformational change is a new signaling mechanism that con-
trols protein function after phosphorylation (Lu et al., 2002b).
In addition to the availability of specific phosphorylated sub-
strates, Pin1 function is normally regulated tightly through multi-
ple mechanisms, including transcriptional regulation and
posttranslational modifications. Pin1 expression is activated by
the E2F family of transcription factors in response to growth sig-
naling, such as activation of Ras or Neu (Ryo et al., 2002). Like
many other E2F target genes (Nevins, 2001), Pin1 transcription
and its protein levels fluctuate during cell cycle progression in
nontransformed cells (Ryo et al., 2002), but are constitutively
elevated in transformed cells (Shen et al., 1998). Pin1 function
is also regulated by protein phosphorylation of itself. Although
the specific kinases and phosphatases involved remain to be
identified, cell cycle-specific phosphorylation of the Pin1 WW
domain inhibits its ability to bind substrates and to regulate the
subcellular localization of Pin1 (Lu et al., 2002b).
The significance of Pin1 regulation is highlighted by the
findings that Pin1 is prevalently overexpressed in human can-
cers and also functions as a critical catalyst at multiple steps in
oncogenic signaling pathways (Figure 2). For example, in breast
cancer, Pin1 is drastically overexpressed and mainly exists in a
hypophosphorylated, presumably active form in a large number
of human breast cancer tissues (Wulf et al., 2001). More impor-
tantly, Pin1 regulates the function of cyclin D1, an essential pro-
tein in breast cancer development (Yu et al., 2001), through
multiple mechanisms (Ryo et al., 2003). Pin1 collaborates with
Ras/JNK signaling to increase the transcriptional activity of Jun
toward cyclin D1 (Figure 2B) (Wulf et al., 2001). It also activates
β-catenin by preventing its binding to the tumor suppressor
APC, which leads to induction of β-catenin downstream target
genes such as cyclin D1, Jun, and Myc (Figure 2B) (Ryo et al.,
2002). Furthermore, Pin1 can directly act on cyclin D1 to
increase its stability (Liou et al., 2002) (Figure 2B). In addition,
Myc can enhance cyclin D1 function by inducing Cdk4 expres-
sion and also directly induce E2F family genes (Nevins, 2001).
These molecules act synergistically to regulate cyclin D1 func-
tion. Indeed, loss of Pin1 function in the mouse causes failure of
the breast epithelial compartment to undergo the massive pro-
liferative changes associated with pregnancy, the major pheno-
type in cyclin D1 null mice (Liou et al., 2002). Finally, Pin1 itself
is an E2F target gene, which can be further upregulated by E2F
F O C U S
Figure 1. Pin1 is a novel postphosphorylation regulator in signal transduc-
tion
In response to growth signals or oncogenic activation, a subset of proteins
are phosphorylated on certain regulatory Ser/Thr-Pro motifs and become
the substrate for Pin1, which alters the conformation of proteins by catalyz-
ing either the trans to cis or the cis to trans isomerization of pSer/Thr-Pro
depending on specific target sites. The results so far support the notion that
the conformational changes following phosphorylation are essential for
controlling the function of at least certain Pin1 substrates. 
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activation in a positive feedback loop involving cyclin D1/Cdks,
E2F, and Rb, as well as Pin1 (Ryo et al., 2002) (Figure 2B). This
positive-feedback mechanism may play a central role in aber-
rant cell proliferation and oncogenesis. In fact, Pin1 overexpres-
sion in normal mammary epithelial cells can confer
anchorage-independent cell growth and other early trans-
formed properties (Ryo et al., 2002). Moreover, Pin1 overex-
pression can also greatly enhance transformed phenotypes
induced by oncogenic Neu and Ras (Ryo et al., 2002). In con-
trast, inhibition of Pin1 dramatically reduces both cell prolifera-
tion and transformation induced by oncogenic Neu and Ras.
This reduction can be reversed by expression of the constitu-
tively active cyclin D1-T286A mutant that is resistant to Pin1
inhibition (Ryo et al., 2002).These results indicate that cyclin D1
is a specific downstream target of Pin1 in the transformation of
mammary epithelial cells.
During cancer development, multiple oncogenic signaling
pathways are often activated, which eventually lead to Pro-
directed phosphorylation and uncontrolled cell proliferation
(Blume-Jensen and Hunter, 2001). The above results have led
us to propose that Pin1 would cooperate with these multiple
oncogenic pathways to promote cell proliferation and transfor-
mation (Ryo et al., 2003). In this model, Pin1 responds to and
amplifies oncogenic signals, functioning as an indispensable
translator and amplifier of oncogenic signaling pathways. A cru-
cial genetic test for this hypothesis will be to study tumor devel-
opment in Pin1-transgenic or Pin1-deficient mice in the
presence or absence of various oncogenes.
Pin1 is prevalently overexpressed in human cancers and is
a molecular target for cancer diagnostics
Overexpression of Pin1 was originally observed in human
breast cancer tissues and breast cancer cell lines (Ryo et al.,
2001; Wulf et al., 2001). This observation has been confirmed
and expanded by a large scale of study comparing Pin1 expres-
sion in several dozen different human tumor types and their cor-
responding normal tissues. Pin1 overexpression is observed in
most commonly encountered cancers such as prostate, breast,
cervical, brain, lung, and colon cancer, but not in others (L. Bao
et al.,  submitted). These results indicate that Pin1 overexpres-
sion is a prevalent and specific event in human cancers. Since
Pin1 is an E2F target gene (Ryo et al., 2002), deregulation of
the Rb/E2F pathway, which is found in many human cancers
(Nevins, 2001), likely plays a significant role in increased Pin1
expression in human cancers. In addition, it would be interesting
to determine whether any genetic mutations or amplifications
might be present in human cancers, which might contribute to
upregulation of Pin1 function in cancer by increasing expression
or abolishing the inhibitory phosphorylation. Any such changes
would provide strong genetic evidence for a critical role of Pin1
in oncogenesis.
Given prevalent overexpression of Pin1 in human cancers
(L. Bao et al., submitted; Ryo et al., 2001; Wulf et al., 2001),
detection of Pin1 expression might help distinguish cancer cells
from normal cells as well as identify cancer patients for possible
Pin1-based cancer therapies. Furthermore, it appears that
determination of Pin1 expression might have an important prog-
nostic value for managing cancer patients. In breast cancer, ele-
vated Pin1 expression strongly correlates with upregulation of
β-catenin (Ryo et al., 2001). Given that β-catenin is a strong and
independent prognostic factor (Lin et al., 2000), these results
suggest that Pin1 may be of significant prognostic value in
oncology.
This notion has been recently supported by a large scale
study correlating Pin1 expression with the clinic outcome of
580 prostate cancer patients who underwent radical prostatec-
tomy by a single surgeon and did not have any preoperative
adjuvant therapy (Ayala et al., 2003). Prostate cancer is the
most common male cancer in the United States, and radical
prostatectomy is a definitive form of therapy for clinically local-
ized prostate cancer. However, approximately one-third of the
patients treated with radical prostatectomy experience pro-
gression even when tumors are confined pathologically to the
prostate. Accurate prediction of the risk of recurrence would be
valuable when considering early adjuvant therapy or some
form of investigational treatments. Currently, there is no validat-
ed prognostic marker capable of reliably distinguishing
between groups of patients who could be safely entered into
watchful waiting protocols versus patients who require, and
would benefit from, definitive surgery/radiation therapy. Thus, a
substantial part of prostate cancer research aims to define
F O C U S
Figure 2. Pin1 functions as a pivotal catalyst for integrating multiple onco-
genic signaling pathways
A: Pin1 is a downstream target of growth factors and functions at multiple
steps in growth signal transduction as well as in eventual cell cycle
progression. 
B: A specific example is given of how Pin1 controls expression and post-
translational stabilization of cyclin D1 in collaboration with other onco-
genes in breast cancer.
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accurate prognostic markers for estimating malignant poten-
tial, with the majority focusing on gene expression profiling
(Dhanasekaran et al., 2001; Singh et al., 2002).
Pin1 is overexpressed in prostate cancer cells both in the
intensity of expression and the percentage of Pin1-positive
cells based on immunocytochemistry (Ayala et al., 2003). More
importantly, Pin1 expression positively correlates with lymph
node metastasis and clinical recurrence (Ayala et al., 2003).
Pin1 expression is determined by visual evaluation to be posi-
tive or negative, and its positive expression is a strong inde-
pendent predictor of recurrence in prostate cancer patients
after radical prostatectomy, which is determined by the reap-
pearance of PSA (prostate cancer specific antigen) (Ayala et
al., 2003). The predictive value of Pin1 expression becomes
even more obvious when Pin1 expression is semiquantitatively
evaluated by automated imaging analysis. This imaging analy-
sis can further discriminate Pin1 staining intensity as well as
the sum index of Pin1 expression that is defined as the sum of
the highest intensity of Pin1 staining and the average percent-
age of Pin1-positive cells (Ayala et al., 2003). A patient with a
high Pin1 sum index has a >8 times greater risk of recurrence
than a patient with a low expression index. Furthermore, Pin1
is also an excellent predictor of recurrence in the subset of
patients with a Gleason score of 6 or 7, where it is almost
impossible to predict clinic outcome (Ayala et al., 2003). Again,
a patient with high Pin1 expression again has over 8 times the
risk of having earlier recurrence than one with low Pin1 expres-
sion. Moreover, Pin1 outperforms other known and currently
used clinicopathologic parameters, including lymph node
metastasis, preoperative PSA levels, Gleason score, surgical
margins, seminal vesicle status, and extracapsular extension
(Ayala et al., 2003). Although it is important to confirm these
results using other independent sets of prostate cancer sam-
ples, these results show that Pin1 expression is at least as
good as, if not better than, currently used postoperatively avail-
able clinicopathologic parameters. It could potentially be uti-
lized in the preoperative setting to assist in choice of treatment.
In addition, a test for Pin1 expression in tumor tissues after rad-
ical prostatectomy might help identify patients who will need
more aggressive therapy.
Pin1 is an attractive molecular target for cancer
therapeutics
In the last several years, signal transduction cascades have
become promising targets for anticancer therapy (Druker,
2002). For example, trastuzumab, the monoclonal antibody
against Her2/neu, is now part of the standard armamentarium
in treating Her2/neu-overexpressed breast cancer patients
(Harries and Smith, 2002), and imatinib, a specific inhibitor of
the Bcr-Abl tyrosine kinase, has been successfully used to treat
chronic myeloid leukemia (Deininger et al., 2003). A number of
features make Pin1 an attractive new drug target for cancer
therapy. First, Pin1 is an enzyme with an extraordinarily high
substrate specificity and well-defined active site (Lu et al.,
1999b; Ranganathan et al., 1997; Shen et al., 1998;Yaffe et al.,
1997). Historically, it has been much easier to develop inhibitors
specific for an enzyme than for a nonenzymatic protein.
Second, Pin1 is prevalently overexpressed in human cancers,
and its expression levels correlate with the poor clinical out-
come (Ayala et al., 2003; L. Bao et al., submitted; Ryo et al.,
2001; Wulf et al., 2001). Third, Pin1 functions as the critical cat-
alyst for multiple oncogenic pathways; its overexpression is able
to confer transforming properties on normal cells and to
enhance transformed phenotype induced by other oncogenes
such as Neu and Ras (Liou et al., 2002; Ryo et al., 2003; Ryo et
al., 2001; Ryo et al., 2002; Wulf et al., 2001). Fourth, inhibition of
Pin1 using antisense PIN1 or dominant negative Pin1 mutants
causes cancer cells to enter mitotic block and apoptosis in tran-
sient transfection (Lu et al., 1996, 2002a; Rippmann et al.,
2000) or suppresses the transformed phenotypes induced by
Ras/Neu (Ryo et al., 2002). Furthermore, this suppression of
transformed phenotypes by inhibition of Pin1 can be reversed
by a constitutively active cyclin D1 mutant that is resistant to
Pin1 inhibition (Ryo et al., 2002). Fifth, Pin1 knockout mice
develop normally to adulthood (Fujimori et al., 1999; Liou et al.,
2002), indicating that an anti-Pin1 therapy might not have gen-
eral toxic effects. It is also worth pointing out that Pin1 knockout
mice do develop several age-dependent phenotypes, including
testicular atrophy, retinal atrophy, and neurodegeneration (Liou
et al., 2002, 2003). Given that these phenotypes occur only
after a long-term loss of Pin1, a short-term treatment with Pin1
inhibitors during cancer therapy is unlikely to have acute side
effects, especially if the inhibitors are not readily absorbed
through the blood-brain and blood-testis barriers. Finally, anoth-
er beneficial feature of Pin1 inhibitors would be that they may
simultaneously inhibit multiple oncogenic signaling pathways,
on which cancer cells depend for growth and survival (Liou et
al., 2002; Ryo et al., 2001, 2002, 2003; Wulf et al., 2001). These
inhibitory activities could perhaps circumvent the characteristic
genetic plasticity that has allowed cancer cells to eventually
evade the toxic effects of most molecularly targeted agents.
Although Pin1 inhibition with antisense strategies and dom-
inant-negative mutants has been employed successfully in vitro
(Lu et al., 1996, 2002a; Rippmann et al., 2000; Ryo et al., 2002),
the feasibility of therapeutic Pin1 inhibition has not yet been
explored, largely due to the lack of highly specific inhibitors. In
contrast to cyclophilins and FK506 binding proteins, where
highly specific inhibitors are well characterized and widely used
clinically (Hunter, 1998), the only known Pin1 inhibitors are the
natural product Juglone (Hennig et al., 1998) and the small mol-
ecule PiB and its derivatives (Uchida et al., 2003). Juglone
covalently inactivates a unique cysteine residue in the active
site of Pin1-type and parvulin-type isomerases. Juglone has
some anticancer activity and has been used as a Pin1 inhibitor
in several studies in vitro (Chao et al., 2001; Rippmann et al.,
2000). However, given that Juglone potently inhibits many other
proteins and enzymes (Chao et al., 2001; Ryo et al., 2003), it is
unlikely to be Pin1-specific in the cell. Unlike Juglone, PiB and
its analogs have been shown to be competitive inhibitors with
low µM IC50 values (Uchida et al., 2003). Furthermore, PiB and
its analogs have been shown to inhibit cell growth of Pin1-con-
taining cell lines, but not Pin1-deficient cells (Uchida et al.,
2003).These results suggest that Pin1 is an important target for
these compounds and further support the idea of utilizing Pin1
inhibitors as anticancer reagents. However, similar to Juglone,
PiB and its analogs also inhibit non-phosphorylation-specific
prolyl isomerases such as Par14 (Hennig et al., 1998; Uchida et
al., 2003), raising the concern about the specificity of these
compounds. In addition, these compounds are quite weak
inhibitors of Pin1. Therefore, there is an urgent need for the
development of highly specific and potent Pin1 inhibitors. In
fact, several pharmaceutical companies have Pin1 inhibitors 
at various preclinical testing stages (e.g., Pintex,
www.pintexpharm.com). Consequently, it is feasible that Pin1-
F O C U S
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specific inhibitors will be developed in the near future. Such
inhibitors might be highly effective anticancer drugs alone or in
combination with established chemotherapeutic drugs or proce-
dures. For example, Pin1 inhibitors might be used to increase
the sensitivity of cancer cells to irradiation therapy as Pin1 null
cells are more sensitive to irradiation, partially due to the fact
that Pin1 is required for DNA damage response (Wulf et al.,
2002; Zacchi et al., 2002; Zheng et al., 2002). Finally, taxol also
induces mitotic arrest and apoptosis via disrupting microtubule
function that is likely different from that resulting from inhibiting
Pin1. Therefore, Pin1 inhibitors might be used in combination
with taxol as part of a novel clinical strategy for cancer therapy.
Alternatively, Pin1 inhibitors might be used in combination with
other drugs that are targeted to various steps of signaling path-
ways (Figure 1A). These combined chemotherapies may
increase their effectiveness and/or reduce chemoresistance, a
major clinical problem associated with current cytotoxic
chemotherapies.
Conclusion and future challenges
Pin1 is a novel postphosphorylation signaling regulator, which
sits at the crossroads of many signaling pathways controlling
cell proliferation and transformation involving Pro-directed
phosphorylation. Following phosphorylation, Pin1 catalyzed
prolyl-isomerization induces conformational changes and
thereby regulates the function of a number of phosphorylated
proteins that play an important role during oncogenesis. Given
that Pin1 is overexpressed in the majority of human cancers
and its expression levels are correlated with poor clinical out-
come in some cancers, Pin1 may function as a critical catalyst
that potentiates multiple oncogenic signaling mechanisms dur-
ing cancer development. As a result, Pin1 inhibitors should
simultaneously inhibit multiple oncogenic signaling pathways,
which may circumvent the characteristic genetic plasticity that
has allowed cancer cells to eventually evade the toxic effects of
most molecularly targeted agents. Therefore, Pin1 represents a
promising new molecular target for cancer diagnostic and thera-
peutics. A major challenge for the future will be to further eluci-
date the molecular mechanisms of Pin1 deregulation during cell
transformation and to determine the in vivo role of Pin1 during
oncogenesis using model systems such as Pin1 knockout and
Pin1 transgenic mouse models in the presence or absence of
other oncogenes. A further and significant challenge will be the
development of highly specific and potent Pin1 inhibitors for
clinical trials and eventually cancer therapies.
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